Vipshop Not Done De...
Health Care: Drugs
Endocyte Inc. (ECYT: NASDAQ)
$14.23 0.07 | 0.49%
05/21/13 - 04:00 PM ET
Company Balance Sheet
| Dec 2012 | Dec 2011 | Dec 2010 | Dec 2009 | |
| Assets | ||||
|---|---|---|---|---|
| Cash and Equivalents | 34.00M | 61.35M | 16.87M | 8.70M |
| Receivables | 5.69M | 0.00 | 0.00 | 0.00 |
| Inventories | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Current Assets | 3.30M | 548.32K | 539.66K | 0.00 |
| Total Current Assets | 184.82M | 129.76M | 20.05M | 24.28M |
| Property, Plant & Equipment, Gross | 5.30M | 3.16M | 3.18M | 2.98M |
| Accumulated Depreciation & Depletion | 2.13M | 2.05M | 2.31M | 2.05M |
| Property, Plant & Equipment, Net | 3.17M | 1.11M | 863.01K | 923.05K |
| Intangibles | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Assets | 26.09M | 811.23K | 300.98K | 61.42K |
| Total Non-Current Assets | 29.25M | 1.92M | 1.16M | 984.47K |
| Liabilities & Shareholder Equity | ||||
| Total Assets | 214.08M | 131.68M | 21.21M | 25.27M |
| Accounts Payable | 3.65M | 2.13M | 2.84M | 1.79M |
| Short Term Debt | 12.65K | 0.00 | 4.32M | 6.26M |
| Other Current Liabilities | 0.00 | 1.54M | 223.03K | 221.03K |
| Total Current Liabilities | 62.47M | 5.47M | 7.67M | 8.81M |
| Long Term Debt | 0.00 | 12.83M | 20.02M | 2.72M |
| Deferred Income Taxes | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Non-Current Liabilities | 51.99M | 0.00 | 637.50K | 0.00 |
| Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 |
| Total Non-Current Liabilities | 52.04M | 12.83M | 110.45M | 92.52M |
| Total Liabilities | 114.51M | 18.30M | 118.13M | 101.33M |
| Preferred Stock Equity | 0.00 | 0.00 | 0.00 | 0.00 |
| Common Stock Equity | 99.57M | 113.37M | -96.91M | -76.06M |
| Common Par | 35.92K | 35.78K | 1.16M | 1.92M |
| Additional Paid In Capital | 255.36M | 251.94M | 0.00 | 0.00 |
| Cumulative Translation Adjustment | 0.00 | 0.00 | 0.00 | 0.00 |
| Retained Earnings | -155.89M | -138.60M | -98.07M | -77.98M |
| Treasury Stock | 0.00 | 0.00 | 0.00 | 0.00 |
| Other Equity Adjustments | 72.75K | -6.26K | 0.00 | 2.18K |
| Total Capitalization | 99.57M | 126.21M | -76.90M | -73.34M |
| Total Equity | 99.57M | 113.37M | -96.91M | -76.06M |
| Total Liabilities & Stock Equity | 214.08M | 131.68M | 21.21M | 25.27M |
| Total Common Shares Outstanding | 35.92M | 35.78M | 27.70M | 27.70M |
| Preferred Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Treasury Shares | 0.00 | 0.00 | 0.00 | 0.00 |
| Basic Weighted Shares Outstanding | 35.86M | 29.00M | 923.01K | 12.66M |
| Diluted Weighted Shares Outstanding | 35.86M | 29.00M | 923.01K | 12.66M |
| Number of Employees | 71 | 61 | 55 | NA |
| Number of Part-Time Employees | 0 | 0 | 0 | NA |
Portfolios with ECYT
- Portfolio NameUser Type
- ContributorStocks Under-$10 Moving Hig...
- ContributorBreakout Stocks Of The Week...
- ContributorStocks Under-$10 Setting Up...
- UserSmart Growth
- ContributorStocks Under-$10 Moving Hig...
- ContributorStocks Under-$10 Moving Hig...
- ContributorEarnings Short Squeeze Play...
- ContributorStocks With Big Insider Buy...
- ContributorStocks Rising On Unusal Vol...
- Contributor8 Health Care Stocks With R...
Latest ECYT Headlines from TheStreet
- Endocyte Announces First Quarter 2013 Earnings Conference Call 04.18.13 | 04:04 pm
- Endocyte Announces Presentations At AACR Annual Meeting 2013 04.03.13 | 04:04 pm
- Endocyte To Present At The Future Leaders In The Biotech Industry Conference 04.01.13 | 08:04 am
- Endocyte To Webcast Investor And Analyst Day In New York City 03.18.13 | 09:03 am
- Endocyte's Investigational Diagnostic Imaging Agent Etarfolatide Identifies Ovarian Cancer And Non-Small Cell Lung Cancer Patients Most Likely To Benefit From Folate Receptor-Targeted Treatment, New Analysis Shows 03.01.13 | 03:03 pm
- Endocyte To Present At Upcoming Conferences In March 02.26.13 | 04:02 pm
- Endocyte Reports Fourth Quarter And Year End 2012 Financial Results And Business Update 02.25.13 | 04:02 pm
- Endocyte To Present At Upcoming Conferences 02.07.13 | 04:02 pm
- Endocyte Announces Fourth Quarter And Full Year 2012 Earnings Conference Call 02.06.13 | 04:02 pm
- Endocyte To Advance Development Of EC1069, A PSMA-Targeted Small Molecule Drug Conjugate Therapy For Prostate Cancer 01.29.13 | 04:01 pm
Press Releases for ECYT
- Merck And Endocyte Announce Acceptance For Review Of European Marketing Authorization Applications For Vintafolide And Companion Diagnostic Etarfolatide For Folate-Receptor Positive Platinum-Resistant Ovarian Cancer - Business Wire 11.27.12 | 08:11 am
- Merck And Endocyte Enter Exclusive Worldwide Agreement To Develop And Commercialize Phase III Cancer Candidate Vintafolide (EC145) - Business Wire 04.16.12 | 07:04 am
Partner Headlines for ECYT
- Company News for April 17, 2012 - Corporate Summary - Zacks 04.17.12 | 10:04 am
- Morning Market Movers - Benzinga 04.16.12 | 09:04 am
- Top 30 Rallying Small Cap Stocks With Significant Institutional Buying - Seeking Alpha 06.29.11 | 09:06 am
- Company News for April 27, 2011 - Corporate Summary - Zacks 04.27.11 | 10:04 am
- 5 Oncology Drugs Available for Partnering - Seeking Alpha 04.27.11 | 09:04 am
- 7 Diverse U.S. IPOs Test Investor Appetites This Week - Seeking Alpha 02.13.11 | 06:02 am
